Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
FLURAZEPAM HYDROCHLORIDE
Mylan IRE Healthcare Limited
N05CD; N05CD01
FLURAZEPAM HYDROCHLORIDE
30
Capsule, hard
Product subject to prescription which may not be renewed (A)
Benzodiazepine derivatives; flurazepam
Marketed
1977-04-01
PAGE 1 OF 7 PACKAGE LEAFLET PAGE 2 OF 7 PACKAGE LEAFLET: INFORMATION FOR THE USER DALMANE 15 AND 30 MG HARD CAPSULES Flurazepam monohydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Dalmane 15 mg or 30 mg hard capsules, which will be called Dalmane capsules thoughout this leaflet. WHAT IS IN THIS LEAFLET: 1. What Dalmane capsules are and what they are used for 2. What you need to know before you take Dalmane capsules 3. How to take Dalmane capsules 4. Possible side effects 5. How to store Dalmane capsules 6. Contents of the pack and other information 1. WHAT DALMANE CAPSULES ARE AND WHAT THEY ARE USED FOR Dalmane capsules contain the active ingredient flurazepam, which belongs to a group of medicines called benzodiazepines. Dalmane capsules are used for severe insomnia (sleeplessness). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DALMANE CAPSULES Do not take Dalmane capsules: - If you have a condition called myasthenia gravis (very weak or tired muscles) - If you have severe breathing difficulties - If you have sleep apnoea syndrome (breathing problems when asleep) - If you have severe pulmonary insufficiency - If you have severe liver disease - If you have a mental illness - If you are allergic to flurazepam - If you are allergic to other similar drugs (benzodiazepines) - If you are allergic to any of the other ingredients of Dalmane capsules (listed in section 6). An allergic reaction may include rash, itching, difficulty breathing or swelling of the face, lips, throat or tongue. WARNINGS Läs hela dokumentet
Health Products Regulatory Authority 26 November 2020 CRN00C1YD Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dalmane 30 mg Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 30 mg flurazepam as flurazepam monohydrochloride. Excipients: Lactose monohydrate 97.7 mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Capsules with opaque black cap and opaque grey body with 'ICN30' printed in red on both cap and body. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _Insomnia_ Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Insomnia_ Treatment should be as short as possible. Generally the duration of treatment varies from a few days to two weeks with a maximum, including tapering off process of four weeks. In certain cases extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient's status. Treatment should be started with the lowest recommended dose. The maximum dose should not be exceeded. Health Products Regulatory Authority 26 November 2020 CRN00C1YD Page 2 of 9 _ _ _Adults:_ The usual dosage is 15-30mg before retiring. 15mg is optimal for most patients. Patients with severe insomnia may require 30mg but residual effects on awakening, associated with anxiolytic effects, are more frequent at this dose. _ _ _Older or debilitated patients:_ Older patients will be particularly susceptible to the adverse effects of Dalmane. The initial dose should not exceed 15mg. If organic brain changes are present, the dosage of Dalmane should be reduced (see section 4.4). _ _ _Use in patients with hepatic and renal impairment:_ The dosage should be reduced in patients with renal or hepatic impairment. Dalmane is contraindicated in patients with severe hepatic failure (see sections 4.3 and 4.4.). _Use in patients with chronic pulmonary insuff Läs hela dokumentet